Language Selection

Get healthy now with MedBeds!
Click here to book your session

Protect your whole family with Orgo-Life® Quantum MedBed Energy Technology® devices.

Advertising by Adpathway

         

 Advertising by Adpathway

Rabbit Globulin Dosing Remains Unresolved in Haploidentical Cell Transplants With Cyclophosphamide

7 hours ago 10

PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY

Orgo-Life the new way to the future

  Advertising by Adpathway

A narrative review published in Clinical and Experimental Medicine reveals that rabbit anti-T-lymphocyte globulin (ATLG; Grafalon) and rabbit anti-thymocyte globulin (ATG; Thymoglobulin) are noninterchangeable polyclonal preparations with unresolved dosing strategies when paired with post-transplant cyclophosphamide (PTCy) in haploidentical hematopoietic cell transplantation (haplo-HCT). Although both agents are widely used across haploidentical transplantation platforms, their primary immunogens, active antibody repertoires, and nominal dose scales differ fundamentally. Despite these substantial biochemical and pharmacological distinctions, direct comparative clinical evidence between the two rabbit globulin formulations remains sparse.

The review emphasizes that the limited available comparative clinical literature cannot establish intrinsic therapeutic differences between the products. Specifically, an existing propensity-matched haploidentical transplant comparison evaluated Thymoglobulin administered at 6 mg/kg against ATLG administered at 10 mg/kg. However, the 10 mg/kg dosage of ATLG was substantially lower than the cumulative totals commonly delivered even in matched-donor transplantation settings. Consequently, observed outcomes regarding post-transplant infection rates and chronic graft-versus-host disease in that comparison reflect dose disparities rather than true biological differences between the formulations.

Currently, serotherapy-based and PTCy-based transplantation platforms continue to coexist worldwide, including at transplant centers outside Western countries. Despite their widespread concurrent application, clinical trials have not established either the optimal rabbit-globulin dose or the optimal PTCy dose within combined prophylaxis regimens. Active-antibody exposure varies widely among recipients and is significantly modified by physiological and procedural variables, most notably the recipient absolute lymphocyte count (ALC), the exact timing of globulin infusion, and overall graft cellularity.

While ATLG-specific absolute lymphocyte count investigations corroborate the link between circulating lymphocytes and antibody exposure, prospectively validated ALC-based dosing models for ATLG remain an unmet need in the field. The authors conclude that rabbit globulin products, conditioning regimens, donor graft sources, PTCy dosing, mycophenolate mofetil, and accompanying immunosuppressive agents must be assessed as an integrated protocol. Until dedicated clinical trials determine precise exposure targets and quantify the net clinical benefit of combination prophylaxis, clinical administration should adhere to product-specific, locally validated regimens.

Subject of Research: Comparative evidence and dosing of rabbit polyclonal globulins in haploidentical transplantation

Article Title: Rabbit ATLG and thymoglobulin in haploidentical hematopoietic cell transplantation product specific evidence and unresolved dosing with PTCy

Article References: Wang, Y., & Xiao, Y. (2026). Rabbit ATLG and thymoglobulin in haploidentical hematopoietic cell transplantation product specific evidence and unresolved dosing with PTCy. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-026-02395-x

Image Credits: AI Generated

DOI: 10.1007/s10238-026-02395-x

Keywords: rabbit ATLG, Thymoglobulin, Grafalon, haploidentical hematopoietic cell transplantation, post-transplant cyclophosphamide, PTCy, serotherapy, polyclonal preparations, chronic graft-versus-host disease, absolute lymphocyte count, graft cellularity, mycophenolate mofetil, combination prophylaxis, active-antibody exposure, matched-donor transplantation, infusion timing

Read Entire Article

         

        

Start the new Vibrations with a Medbed Franchise today!  

Protect your whole family with Quantum Orgo-Life® devices

  Advertising by Adpathway